Ipca Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,910 Cr +13.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
IL

Ipca Laboratories Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Ipca Laboratories Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,388Cr
+6.3% YoY
−0.2% QoQ
Net profit
₹307Cr
+379.7% YoY
−15.7% QoQ
Margin
20%
+1 pp YoY
−2 pp QoQ
Price₹1,911
Market cap₹44.0K Cr
P/E32.0

The short version

Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.

From Ipca Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms.
  • Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth.
  • Unichem, a subsidiary, is expected to grow around 10% in the current financial year.
  • U.S. business showed a 14% growth in FY26; continued growth is anticipated next year.
  • CIS market expected to grow around 10%-11%; domestic India market around 12%-13%.
  • Generic business including U.S. and Europe expected to grow around 12%-13%.
  • Launches planned: Ipca to commercialize 6-8 products in FY27; Unichem to launch 5-6 products.

2 more points from Ipca Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- There is mention of a U.S. formulation facility under construction at Pisgah Labs, expected to be commissioned by Q4 of the current financial year, with meaningful turnover from this plant anticipated only in the next financial year.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points related to order position and outlook include: - The U.S. API facility is seeing a good order position currently, indicating healthy demand. - Unichem's current financial year is expected to grow around 10% with improving EBITDA margins. - New product launches are planned: Ipca expects to commercialize 6 to 8 products in the current year; Unichem to launch 5 to 6 products.

2 more points from Ipca Laboratories Ltd's call on order book

Create a free account to keep reading this call

Ipca Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Ipca Laboratories Ltd Q4 FY26 results — key figures

Ipca Laboratories Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue2,3882,247+6.3%2,392-0.2%
Operating profit (EBITDA)484429+12.8%533-9.2%
Operating margin20%19%+1 pp22%-2 pp
Profit before tax404128+215.6%446-9.4%
Net profit (PAT)30764+379.7%364-15.7%
EPS (₹)11.792.67+341.6%12.86-8.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.9K Cr, net profit ₹389 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Ipca Laboratories Ltd Q4 FY26 results?

Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.

What is Ipca Laboratories Ltd share price analysis?

Ipca Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 32.0 with a market cap of ₹43,997 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ipca Laboratories Ltd planning capital expenditure?

- There is mention of a U.S.

Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.